Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionATP-dependent chromatin remodeler activity

SMARCA5 HELLS

6.86e-0437212GO:0140658
GeneOntologyMolecularFunctionchromatin binding

ELK1 SMARCA5 ELK4 GABPA HELLS

8.50e-04739215GO:0003682
GeneOntologyCellularComponentpericentric heterochromatin

SMARCA5 HELLS

4.68e-0432212GO:0005721
GeneOntologyCellularComponentchromosome, centromeric region

KNTC1 SMARCA5 HELLS

2.54e-03276213GO:0000775
DomainEts_dom

ELK1 ELK4 GABPA

3.94e-0628213IPR000418
DomainEts

ELK1 ELK4 GABPA

3.94e-0628213PF00178
DomainETS_DOMAIN_1

ELK1 ELK4 GABPA

3.94e-0628213PS00345
DomainETS_DOMAIN_2

ELK1 ELK4 GABPA

3.94e-0628213PS00346
DomainETS_DOMAIN_3

ELK1 ELK4 GABPA

3.94e-0628213PS50061
DomainETS

ELK1 ELK4 GABPA

3.94e-0628213SM00413
DomainWD40_repeat_dom

KNTC1 GEMIN5 MED16 GTF3C4

3.03e-04297214IPR017986
DomainSNF2_N

SMARCA5 HELLS

5.85e-0432212PF00176
DomainSNF2_N

SMARCA5 HELLS

5.85e-0432212IPR000330
Domain-

ELK1 ELK4 GABPA

1.79e-032182131.10.10.10
DomainWHTH_DNA-bd_dom

ELK1 ELK4 GABPA

2.40e-03242213IPR011991
DomainHelicase_C

SMARCA5 HELLS

6.36e-03107212PF00271
DomainHELICc

SMARCA5 HELLS

6.36e-03107212SM00490
DomainHelicase_C

SMARCA5 HELLS

6.48e-03108212IPR001650
DomainHELICASE_CTER

SMARCA5 HELLS

6.59e-03109212PS51194
DomainHELICASE_ATP_BIND_1

SMARCA5 HELLS

6.59e-03109212PS51192
DomainDEXDc

SMARCA5 HELLS

6.59e-03109212SM00487
DomainHelicase_ATP-bd

SMARCA5 HELLS

6.71e-03110212IPR014001
DomainLRR

LRRTM4 DRC3

2.12e-02201212PS51450
DomainLRR_1

LRRTM4 DRC3

2.48e-02219212PF00560
PathwayWP_ID_SIGNALING

ELK1 ELK4

1.44e-0416162M39359
PathwayWP_SEROTONIN_RECEPTOR_467_AND_NR3C_SIGNALING

ELK1 ELK4

2.04e-0419162M39358
PathwayWP_SEROTONIN_RECEPTOR_2_AND_ELKSRFGATA4_SIGNALING

ELK1 ELK4

2.27e-0420162M39485
Pubmed

The ETS transcription factors ELK1 and GABPA regulate different gene networks to control MCF10A breast epithelial cell migration.

ELK1 GABPA

3.82e-07222223284628
Pubmed

ERK Signaling Controls Innate-like CD8+ T Cell Differentiation via the ELK4 (SAP-1) and ELK1 Transcription Factors.

ELK1 ELK4

3.82e-07222230068599
Pubmed

ETS-family genes in pancreatic development.

ELK1 ELK4 GABPA

7.94e-072922317907201
Pubmed

Articular cartilage endurance and resistance to osteoarthritic changes require transcription factor Erg.

ELK1 ELK4 GABPA

7.94e-072922326097038
Pubmed

Elk3 deficiency causes transient impairment in post-natal retinal vascular development and formation of tortuous arteries in adult murine retinae.

ELK1 ELK4

1.15e-06322225203538
Pubmed

Binding and inhibition of the ternary complex factor Elk-4/Sap1 by the adapter protein Dok-4.

ELK1 ELK4

1.15e-06322228275114
Pubmed

Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway.

ELK1 ELK4

1.15e-0632229644975
Pubmed

Ets transcription factors ER81 and Elk1 regulate the transcription of the human presenilin 1 gene promoter.

ELK1 GABPA

1.15e-06322212750007
Pubmed

Ternary complex factors SAP-1 and Elk-1, but not net, are functionally equivalent in thymocyte development.

ELK1 ELK4

1.15e-06322220554967
Pubmed

Elucidation of the ELK1 target gene network reveals a role in the coordinate regulation of core components of the gene regulation machinery.

ELK1 GABPA

1.15e-06322219687146
Pubmed

Adhesion regulates MAP kinase/ternary complex factor exchange to control a proliferative transcriptional switch.

ELK1 ELK4

1.15e-06322223063436
Pubmed

Net, a new ets transcription factor that is activated by Ras.

ELK1 ELK4

1.15e-0632227958835
Pubmed

Golgi stress-induced transcriptional changes mediated by MAPK signaling and three ETS transcription factors regulate MCL1 splicing.

ELK1 GABPA

2.29e-06422229118074
Pubmed

Locations of the ets subfamily members net, elk1, and sap1 (ELK3, ELK1, and ELK4) on three homologous regions of the mouse and human genomes.

ELK1 ELK4

2.29e-0642228575773
Pubmed

Identification of the intermediate filament protein synemin/SYNM as a target of myocardin family coactivators.

ELK1 ELK4

2.29e-06422231461342
Pubmed

The ETS-domain transcription factor family.

ELK1 ELK4

2.29e-0642229570133
Pubmed

Activation of the Sap-1a transcription factor by the c-Jun N-terminal kinase (JNK) mitogen-activated protein kinase.

ELK1 ELK4

3.82e-0652229020136
Pubmed

The expression of ELK transcription factors in adult DRG: Novel isoforms, antisense transcripts and upregulation by nerve damage.

ELK1 ELK4

3.82e-06522220304071
Pubmed

Comparative analysis of the ternary complex factors Elk-1, SAP-1a and SAP-2 (ERP/NET).

ELK1 ELK4

3.82e-0652227540136
Pubmed

TPL-2 Inhibits IFN-β Expression via an ERK1/2-TCF-FOS Axis in TLR4-Stimulated Macrophages.

ELK1 ELK4

5.72e-06622235082159
Pubmed

Id helix-loop-helix proteins inhibit nucleoprotein complex formation by the TCF ETS-domain transcription factors.

ELK1 ELK4

5.72e-06622210022839
Pubmed

c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells.

ELK1 ELK4

5.72e-06622211313879
Pubmed

Endothelial SRF/MRTF ablation causes vascular disease phenotypes in murine retinae.

ELK1 ELK4

5.72e-06622223563308
Pubmed

Serum response factor, its cofactors, and epithelial-mesenchymal signaling in urinary bladder smooth muscle formation.

ELK1 ELK4

8.01e-06722216466398
Pubmed

Convergence of MAP kinase pathways on the ternary complex factor Sap-1a.

ELK1 ELK4

8.01e-0672229130707
Pubmed

USP11-mediated LSH deubiquitination inhibits ferroptosis in colorectal cancer through epigenetic activation of CYP24A1.

GTF3C4 HELLS

1.07e-05822237414755
Pubmed

p38-2, a novel mitogen-activated protein kinase with distinct properties.

ELK1 ELK4

1.37e-0592229235954
Pubmed

The in vivo Interaction Landscape of Histones H3.1 and H3.3.

GTF3C4 SMARCA5 GABPA TMA16 HELLS

3.31e-0560822536089195
Pubmed

Maintenance of silent chromatin through replication requires SWI/SNF-like chromatin remodeler SMARCAD1.

GTF3C4 SMARCA5 HELLS

5.32e-0511622321549307
Pubmed

Distinct roles of androgen receptor, estrogen receptor alpha, and BCL6 in the establishment of sex-biased DNA methylation in mouse liver.

ELK4 GABPA

1.05e-042422234215813
Pubmed

ETS-dependent regulation of a distal Gata4 cardiac enhancer.

ELK4 GABPA

1.05e-042422222056786
Pubmed

Interactome Analysis of the Nucleocapsid Protein of SARS-CoV-2 Virus.

GTF3C4 SPTB TMA16

1.35e-0415922334578187
Pubmed

Reciprocal interaction between SIRT6 and APC/C regulates genomic stability.

GEMIN5 MED16 GTF3C4 SMARCA5

1.54e-0444022434244565
Pubmed

An Oct4-centered protein interaction network in embryonic stem cells.

MED16 SMARCA5 HELLS

1.57e-0416722320362541
Pubmed

TRIP12 promotes small-molecule-induced degradation through K29/K48-branched ubiquitin chains.

MED16 SMARCA5

1.99e-043322233567268
Pubmed

Large-scale identification of c-MYC-associated proteins using a combined TAP/MudPIT approach.

GTF3C4 SMARCA5 HELLS

3.11e-0421122317314511
Pubmed

Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.

GEMIN5 MED16 GTF3C4 SMARCA5 HELLS

3.63e-04101422532416067
Pubmed

The polycomb group protein L3mbtl2 assembles an atypical PRC1-family complex that is essential in pluripotent stem cells and early development.

SMARCA5 HELLS

4.78e-045122222770845
Pubmed

PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.

KNTC1 MED16 GABPA TMA16 HELLS

5.34e-04110322534189442
Pubmed

Inflammation-dependent overexpression of c-Myc enhances CRL4DCAF4 E3 ligase activity and promotes ubiquitination of ST7 in colitis-associated cancer.

KNTC1 ELK4 ATG2A

5.54e-0425722330945288
Pubmed

Screening large numbers of expression patterns of transcription factors in late stages of the mouse thymus.

ELK1 ELK4 GABPA

5.92e-0426322320932939
GeneFamilyETS transcription factor family

ELK1 ELK4 GABPA

1.49e-0628153534
GeneFamilyWD repeat domain containing

GEMIN5 MED16

1.94e-02262152362
CoexpressionTURJANSKI_MAPK14_TARGETS

ELK1 ELK4

3.01e-0510222M14718
CoexpressionTURJANSKI_MAPK1_AND_MAPK2_TARGETS

ELK1 ELK4

4.42e-0512222M15804
CoexpressionAtlasfacebase_RNAseq_e8.5_FloorPlate_2500_K3

GEMIN5 BCHE ANKRD37 SMARCA5 SPTB TMA16 LRRTM4 HELLS

1.85e-051371208facebase_RNAseq_e8.5_FloorPlate_2500_K3
CoexpressionAtlasfacebase_RNAseq_e8.5_NeuroEpith_hindBrain_2500_K1

GEMIN5 BCHE ANKRD37 SMARCA5 TMA16 LRRTM4 HELLS

6.02e-051164207facebase_RNAseq_e8.5_NeuroEpith_hindBrain_2500_K1
CoexpressionAtlasfacebase_RNAseq_e8.5_NeuroEpith_hindBrain_2500

GEMIN5 BCHE ANKRD37 SMARCA5 TMA16 LRRTM4 HELLS

1.52e-041347207facebase_RNAseq_e8.5_NeuroEpith_hindBrain_2500
CoexpressionAtlasMESO-15 amniotic fluid MSC_vs_MESO-15 blastocyst-Confounder_removed-fold2.0_adjp0.05

KNTC1 GEMIN5 BCHE GTF3C4 SMARCA5 TMA16 HELLS

2.71e-041479207PCBC_ratio_MESO-15 amniotic fluid MSC_vs_MESO-15 blastocyst_cfr-2X-p05
CoexpressionAtlaskidney_e10.5_UretericTip_HoxB7_k-means-cluster#4_top-relative-expression-ranked_1000

KNTC1 SMARCA5 TMA16 HELLS

2.79e-04348204gudmap_kidney_e10.5_UretericTip_HoxB7_k4_1000
CoexpressionAtlasDevelopingGonad_e14.5_ epididymis_emap-29141_k-means-cluster#5_top-relative-expression-ranked_1000

GEMIN5 SMARCA5

4.92e-0435202gudmap_developingGonad_e14.5_ epididymis_1000_k5
CoexpressionAtlasfacebase_RNAseq_e8.5_NeuroEpith_nonFloor_2500

BCHE ANKRD37 SMARCA5 TMA16 LRRTM4 HELLS

6.33e-041202206facebase_RNAseq_e8.5_NeuroEpith_nonFloor_2500
CoexpressionAtlaskidney_e10.5_UretericTip_HoxB7_top-relative-expression-ranked_1000

KNTC1 ANKRD37 SMARCA5 TMA16 HELLS

6.73e-04787205gudmap_kidney_e10.5_UretericTip_HoxB7_1000
CoexpressionAtlasDevelopingGonad_e16.5_ovary_emap-9563_top-relative-expression-ranked_1000

GEMIN5 SMARCA5 LRRTM4 DRC3 HELLS

7.05e-04795205gudmap_developingGonad_e16.5_ovary_1000
CoexpressionAtlasfacebase_RNAseq_e9.5_MandArch_2500_K3

GEMIN5 MED16 GTF3C4 SMARCA5 TMA16 HELLS

8.09e-041259206facebase_RNAseq_e9.5_MandArch_2500_K3
ToppCellLPS-IL1RA+antiTNF-Myeloid-Monocytes,_Macrophages-Erythroid|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

KNTC1 MED16 ELK1 DRC3

9.44e-071552244559e3011514041b65c17ae4ede29da202bce14c
ToppCellControl-immature_Neutrophil-|Control / Disease condition and Cell class

GEMIN5 LRRTM4 HELLS

9.79e-05184223c4e8ba82a6aa76c46f05a71d5f1c7926555318cf
ToppCellPBMC-Control-Myeloid-Neutrophil-immature_Neutrophil|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GEMIN5 LRRTM4 HELLS

9.79e-05184223a8c6028d745aaa6ee7842259238694cb50ce0526
ToppCellPBMC-Control-Myeloid-Neutrophil-immature_Neutrophil-Neu_4|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GEMIN5 LRRTM4 HELLS

9.79e-05184223081d045f3bc98a36f342de7d50f39c9a888dd7eb
ToppCellControl-Myeloid_G-immature_Neutrophil|Control / Disease group, lineage and cell class

GEMIN5 LRRTM4 HELLS

9.79e-0518422345f873236f7e90fb78c8e291d3b5b92d121acec9
ToppCellControl-immature_Neutrophil|Control / Disease condition and Cell class

GEMIN5 LRRTM4 HELLS

9.79e-051842232fdae5c6b3eb2232881d933a8c1061fda3623016
ToppCellPBMC-Control-Myeloid-Neutrophil-immature_Neutrophil|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)

GEMIN5 LRRTM4 HELLS

9.79e-0518422384c20730cd92b9aaa50077d7b625e37e7f9e91d2
ToppCellPBMC-Control-Myeloid-Neutrophil-immature_Neutrophil-Neu_4|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

GEMIN5 LRRTM4 HELLS

9.79e-05184223d31d4116d1d196633784863781fa45673607a421
ToppCellCOVID-19-T_cells-Cycling_NK/T_cells|COVID-19 / group, cell type (main and fine annotations)

KNTC1 SPTB HELLS

1.16e-04195223764ed100c28d9bc93ee5ecabc5291c8f184d78da
ToppCellControl-Neu_4|Control / 5 Neutrophil clusters in COVID-19 patients

GEMIN5 LRRTM4 HELLS

1.18e-04196223b8b7b54ca17a08fa775507bb22b1c7248ada8f40
DrugX 48

ELK1 ELK4

4.88e-0511222CID000407233
Druglead arsenate

KNTC1 GEMIN5 BCHE

8.43e-0589223CID000024572
Drug15d-PGJ2; Down 200; 10uM; MCF7; HT_HG-U133A

MED16 ELK4 TMA16

7.48e-041872231656_DN
DrugLY 294002; Down 200; 10uM; MCF7; HT_HG-U133A

MED16 ELK1 ELK4

7.60e-041882235224_DN
DrugICI182,780; Down 200; 1uM; MCF7; HT_HG-U133A

MED16 ELK4 TMA16

7.60e-041882237091_DN
DrugMetampicillin sodium salt [6489-61-8]; Up 200; 10.4uM; PC3; HT_HG-U133A

MED16 ELK4 TMA16

8.08e-041922232123_UP
DrugIndomethacin [53-86-1]; Down 200; 11.2uM; MCF7; HT_HG-U133A

MED16 ELK1 TMA16

8.20e-041932237409_DN
Drugionomycin calcium salt; Down 200; 2uM; MCF7; HT_HG-U133A_EA

ELK1 ELK4 HELLS

8.20e-04193223979_DN
DrugPHA-00846566E [724718-26-7]; Up 200; 10uM; PC3; HT_HG-U133A

MED16 SMARCA5 TMA16

8.32e-041942237086_UP
DrugMinaprine dihydrochloride [25953-17-7]; Down 200; 10.8uM; HL60; HG-U133A

MED16 SMARCA5 TMA16

8.45e-041952231968_DN
DrugLevamisole hydrochloride [16595-80-5]; Up 200; 16.6uM; HL60; HG-U133A

GTF3C4 ATG2A DRC3

8.45e-041952231410_UP
DrugDL-PPMP; Down 200; 2uM; MCF7; HT_HG-U133A_EA

ELK1 SMARCA5 TMA16

8.45e-041952231121_DN
DrugOxethazaine [126-27-2]; Down 200; 8.6uM; HL60; HG-U133A

MED16 ELK1 SMARCA5

8.45e-041952231984_DN
DrugTrimethoprim [738-70-5]; Up 200; 13.8uM; PC3; HT_HG-U133A

MED16 SMARCA5 ATG2A

8.45e-041952237377_UP
Drugwortmannin from Penicillium funiculosum; Down 200; 0.01uM; MCF7; HT_HG-U133A

MED16 ELK1 ELK4

8.45e-041952231668_DN
DrugDelcorine; Down 200; 8.4uM; MCF7; HT_HG-U133A

ELK1 ELK4 TMA16

8.45e-041952234737_DN
Drug2-butenal

ANKRD37 GTF3C4 ELK4

8.45e-04195223ctd:C012796
DrugLY 294002; Down 200; 0.1uM; PC3; HT_HG-U133A

MED16 SMARCA5 ELK4

8.58e-041962231216_DN
DrugEsculin Hydrate [531-75-9]; Down 200; 11.8uM; MCF7; HT_HG-U133A

ELK1 ELK4 TMA16

8.58e-041962235411_DN
Drugsulfasalazine; Down 200; 100uM; MCF7; HG-U133A

SMARCA5 ELK4 SPTB

8.58e-04196223204_DN
DrugPhenylpropanolamine hydrochloride [154-41-6]; Up 200; 21.4uM; MCF7; HT_HG-U133A

MED16 ELK1 ATG2A

8.58e-041962235298_UP
DrugNalidixic acid sodium salt hydrate; Down 200; 14.6uM; PC3; HT_HG-U133A

ELK1 ELK4 TMA16

8.58e-041962237367_DN
DrugAndrosterone [53-41-8]; Up 200; 13.8uM; HL60; HT_HG-U133A

MED16 ELK4 SPTB

8.70e-041972231296_UP
DrugN6-methyladenosine [1867-73-8]; Up 200; 14.2uM; MCF7; HT_HG-U133A

MED16 ELK4 ATG2A

8.70e-041972235332_UP
DrugPropylthiouracil [51-52-5]; Down 200; 23.4uM; MCF7; HT_HG-U133A

MED16 ELK4 ATG2A

8.70e-041972232837_DN
DrugTrimeprazine tartrate [4330-99-8]; Down 200; 5.4uM; MCF7; HT_HG-U133A

MED16 ELK1 TMA16

8.70e-041972233478_DN
DrugFluocinonide [356-12-7]; Down 200; 8uM; MCF7; HT_HG-U133A

MED16 ELK1 ELK4

8.70e-041972233933_DN
DrugGuanfacine hydrochloride [29110-48-3]; Up 200; 14.2uM; HL60; HT_HG-U133A

MED16 GTF3C4 ELK1

8.70e-041972231279_UP
DrugHarpagoside [19210-12-9]; Up 200; 8uM; PC3; HT_HG-U133A

MED16 SPTB DRC3

8.70e-041972236636_UP
Drugnordihydroguaiaretic acid; Down 200; 1uM; MCF7; HT_HG-U133A_EA

ELK1 ELK4 C1orf216

8.83e-041982231061_DN
DrugFlucloxacillin sodium [1847-24-1]; Up 200; 8.4uM; PC3; HT_HG-U133A

MED16 ELK4 SPTB

8.83e-041982235102_UP
DrugTenoxicam [59804-37-4]; Up 200; 11.8uM; PC3; HT_HG-U133A

MED16 SPTB LRRTM4

8.83e-041982234102_UP
DrugFusidic acid sodium salt [751-94-0]; Up 200; 7.4uM; MCF7; HT_HG-U133A

MED16 ELK4 TMA16

8.83e-041982232647_UP
DrugTadjakonine [11087-94-8]; Up 200; 7.4uM; HL60; HT_HG-U133A

MED16 ELK4 SPTB

8.83e-041982232165_UP
DrugPropofol [2078-54-8]; Up 200; 22.4uM; PC3; HT_HG-U133A

ELK1 SPTB DRC3

8.83e-041982236707_UP
DrugCarbinoxamine maleate salt [3505-38-2]; Down 200; 9.8uM; MCF7; HT_HG-U133A

MED16 ELK1 C1orf216

8.83e-041982233466_DN
DrugFluocinonide [356-12-7]; Down 200; 8uM; MCF7; HT_HG-U133A

MED16 ELK1 TMA16

8.83e-041982233414_DN
DrugHydroquinine hydrobromide hydrate [304695-81-6]; Up 200; 9.4uM; HL60; HG-U133A

MED16 ELK1 ELK4

8.83e-041982231775_UP
DrugFlumequine [42835-25-6]; Down 200; 15.4uM; MCF7; HT_HG-U133A

MED16 ELK4 ATG2A

8.83e-041982235529_DN
DrugHomatropine hydrobromide (R,S) [51-56-9]; Up 200; 11.2uM; PC3; HT_HG-U133A

MED16 ELK1 ELK4

8.83e-041982231806_UP
DrugMidecamycin [35457-80-8]; Down 200; 5uM; PC3; HG-U133A

MED16 SMARCA5 HELLS

8.83e-041982231943_DN
DrugSB 203580; Down 200; 1uM; PC3; HT_HG-U133A

MED16 ELK1 ELK4

8.83e-041982237066_DN
DrugAcetazolamide [59-66-5]; Down 200; 18uM; HL60; HT_HG-U133A

ELK1 TMA16 ATG2A

8.83e-041982231850_DN
DrugCinoxacin [28657-80-9]; Up 200; 15.2uM; PC3; HT_HG-U133A

MED16 ELK4 SPTB

8.96e-041992235783_UP
DrugKhellin [82-02-0]; Up 200; 15.4uM; HL60; HG-U133A

MED16 SPTB ATG2A

8.96e-041992232004_UP
DrugH-7 dihydrochloride; Up 200; 100uM; PC3; HT_HG-U133A

ELK1 ELK4 SPTB

8.96e-041992235968_UP
DrugAmbroxol hydrochloride [23828-92-4]; Up 200; 9.6uM; HL60; HG-U133A

ELK1 SMARCA5 SPTB

8.96e-041992231623_UP
Drug(-)-MK 801 hydrogen maleate [77086-19-2]; Down 200; 11.8uM; MCF7; HT_HG-U133A

MED16 ELK1 TMA16

8.96e-041992235003_DN
DrugNicardipine hydrochloride [54527-84-3]; Up 200; 7.8uM; HL60; HG-U133A

ELK1 SMARCA5 TMA16

8.96e-041992231600_UP
DrugPentoxifylline [6493-05-6]; Up 200; 14.4uM; HL60; HG-U133A

MED16 ELK4 SPTB

8.96e-041992231444_UP
DrugBenzydamine hydrochloride [132-69-4]; Up 200; 11.6uM; HL60; HG-U133A

MED16 ELK1 SPTB

8.96e-041992231552_UP
DrugHarpagoside [19210-12-9]; Up 200; 8uM; MCF7; HT_HG-U133A

MED16 ELK4 TMA16

8.96e-041992237355_UP
DrugCefoperazone dihydrate; Down 200; 5.8uM; HL60; HG-U133A

MED16 GTF3C4 TMA16

8.96e-041992231627_DN
DrugPiperacetazine [3819-00-9]; Down 200; 9.8uM; MCF7; HT_HG-U133A

ELK1 ELK4 TMA16

8.96e-041992237191_DN
DrugPiracetam [7491-74-9]; Down 200; 28.2uM; PC3; HT_HG-U133A

MED16 ELK1 SMARCA5

9.09e-042002235043_DN
DrugW-13, hydrochloride; Up 200; 10uM; MCF7; HG-U133A

MED16 ELK1 ELK4

9.09e-04200223643_UP
Diseaset-cell surface glycoprotein CD8 beta chain measurement

MED16 BCHE

3.18e-064222EFO_0803135
Diseaseintegrin alpha-5 measurement

MED16 BCHE

3.18e-064222EFO_0802637
Diseaseprotocadherin beta-1 measurement

MED16 BCHE

3.18e-064222EFO_0802972
Diseasehistone acetyltransferase type b catalytic subunit measurement

MED16 BCHE

3.18e-064222EFO_0020452
Diseaseuncharacterized protein C3orf18 measurement

MED16 BCHE

5.30e-065222EFO_0802193
Diseaseadenylyltransferase and sulfurtransferase MOCS3 measurement

MED16 BCHE

5.30e-065222EFO_0802257
Diseaseaugurin measurement

MED16 BCHE

5.30e-065222EFO_0801399
DiseaseC-type lectin domain family 4 member D measurement

MED16 BCHE

5.30e-065222EFO_0802347
Diseasev-set and transmembrane domain-containing protein 4 measurement

MED16 BCHE

7.95e-066222EFO_0803247
Diseasepeptidyl-prolyl cis-trans isomerase-like 2 measurement

MED16 BCHE

7.95e-066222EFO_0801877
Diseasebaculoviral IAP repeat-containing protein 5 measurement

MED16 BCHE

1.11e-057222EFO_0020174
DiseaseC-C motif chemokine 1 measurement

MED16 BCHE

1.11e-057222EFO_0008041
Diseaseuroplakin-3b-like protein measurement

MED16 BCHE

1.11e-057222EFO_0802204
Diseaseglutathione S-transferase A4 measurement

MED16 BCHE

1.11e-057222EFO_0801637
Diseasetumor necrosis factor receptor superfamily member 3 measurement

MED16 BCHE

1.48e-058222EFO_0020813
Diseasealpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 measurement

MED16 BCHE

1.48e-058222EFO_0801373
Diseasedesmoglein-1 measurement

MED16 BCHE

1.48e-058222EFO_0020321
Diseasekallikrein-6 measurement

MED16 BCHE

1.48e-058222EFO_0801739
Diseaseprotein sel-1 homolog 2 measurement

MED16 BCHE

1.48e-058222EFO_0801962
Diseasechromobox protein homolog 5 measurement

MED16 BCHE

1.48e-058222EFO_0020258
Diseasecyclin-dependent kinase 5:cyclin-dependent kinase 5 activator 1 complex measurement

MED16 BCHE

1.90e-059222EFO_0020296
Diseaseepididymal-specific lipocalin-10 measurement

MED16 BCHE

1.90e-059222EFO_0801576
Diseasemast cell-expressed membrane protein 1 measurement

MED16 BCHE

1.90e-059222EFO_0801787
Diseaseinterleukin-34 measurement

MED16 BCHE

1.90e-059222EFO_0020505
Diseaseendothelin-converting enzyme 1 measurement

MED16 BCHE

1.90e-059222EFO_0008121
Diseasestromal interaction molecule 1 measurement

MED16 BCHE

2.38e-0510222EFO_0802093
Diseaseaxin-2 measurement

MED16 BCHE

2.38e-0510222EFO_0801400
Diseaseinterleukin-37 measurement

MED16 BCHE

2.38e-0510222EFO_0020506
Diseasetropomyosin beta chain measurement

MED16 BCHE

2.38e-0510222EFO_0020787
Diseaseinsulin growth factor-like family member 3 measurement

MED16 BCHE

2.38e-0510222EFO_0801700
DiseasePR domain zinc finger protein 1 measurement

MED16 BCHE

2.91e-0511222EFO_0801904
Diseaseinterleukin-10 receptor subunit alpha measurement

MED16 BCHE

2.91e-0511222EFO_0021890
Diseasetyrosine-protein kinase ZAP-70 measurement

MED16 BCHE

3.49e-0512222EFO_0020833
Diseaseoncostatin-M measurement

MED16 BCHE

3.49e-0512222EFO_0010792
Diseasekallikrein-12 measurement

MED16 BCHE

4.12e-0513222EFO_0008194
Diseasecentral nervous system disease (implicated_via_orthology)

GEMIN5 SMARCA5

6.33e-0516222DOID:331 (implicated_via_orthology)
Diseaseschizophrenia (is_marker_for)

BCHE ELK1

4.93e-0444222DOID:5419 (is_marker_for)
DiseaseHuntington's disease (is_marker_for)

BCHE ELK1

7.15e-0453222DOID:12858 (is_marker_for)
Diseasecomplement factor D measurement

MED16 LRRTM4

2.18e-0393222EFO_0020283

Protein segments in the cluster

PeptideGeneStartEntry
LFDQQLALQWVQKNI

BCHE

196

P06276
TLWQFLLQLLREQGN

ELK1

6

P19419
LQWIRGLQHQLIDQQ

C1orf216

181

Q8TAB5
DLWLIEQDLNQQLQA

ATG2A

326

Q2TAZ0
FLLWQLQTGADLNQQ

ANKRD37

46

Q7Z713
LQNNLSELWSLLNFL

HELLS

386

Q9NRZ9
LKSNQFAGLNQLIWL

LRRTM4

76

Q86VH4
DQFEIQLNQQLWSLI

LRRC37A5P

21

Q49AS3
NNGQIQLWQFLLELL

GABPA

316

Q06546
LQLWNGLLQKLLGFN

KNTC1

1976

P50748
NFQLLGFQNLLEWQA

OR11L1

11

Q8NGX0
LQALQQLLQWVGDFV

MED16

611

Q9Y2X0
TLWQFLLQLLQKPQN

ELK4

6

P28324
LWQFENLRKLQLDNN

DRC3

61

Q9H069
QQQQQLGLWVIAGIL

SLC39A13

146

Q96H72
QEQKPLQQLWNAILL

RNF215

246

Q9Y6U7
LLQQQGQLWTNSLRI

nan

96

Q6ZTK2
LLANNWVGAQEALQL

GEMIN5

1096

Q8TEQ6
LQNFLQNCQELTLWI

SPTB

1276

P11277
LTIQANLNRLQWVQL

GTF3C4

191

Q9UKN8
NVLIEDLLNWNNLYI

TAMM41

116

Q96BW9
QNNLHELWSLLNFLL

SMARCA5

341

O60264
LRLNLVGEKLQWFQN

TMA16

46

Q96EY4